Breaking News, Collaborations & Alliances

Astellas Pharma and Pantherna Therapeutics Enter New Technology Evaluation Agreement

Pantherna's mRNA platform & Astellas' drug discovery capabilities will be combined to generate mRNA-based regenerative medicine programs.

Author Image

By: Charlie Sternberg

Associate Editor

Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation).   This agreement expands the scope of the technology evaluation agreement for research, which Astellas and Pantherna entered into in 2021, to include new target organ.   Pantherna owns a proprietary platform of unique mRNA molecules (PTXmRNAs) for enhancing the efficie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters